Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
boston blog main
boston top stories
10
×
clinical trials
10
×
life sciences
national blog main
national top stories
novartis
10
×
san francisco blog main
10
×
san francisco top stories
national
raleigh-durham blog main
raleigh-durham top stories
boulder/denver blog main
boulder/denver top stories
detroit blog main
detroit top stories
indiana blog main
indiana top stories
new york blog main
new york top stories
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
fda
abbvie
amgen
gene therapy
immunotherapy
cancer
glaxosmithkline
johnson & johnson
medical devices
pfizer
roche
What
roundup
bio
drug
new
news
approval
biofourmis
biotech
blood
cancer
days
devices
fda
head
ipo
nash
patients
public
won
abbvie’s
according
advantages
ahead
akcea
america
american
amgen
analytics
annual
ash
august
bar
biogen
biogen’s
biopharmaceutical
borne
brings
broader
bucks
busy
Language
unset
Current search:
biotech
×
novartis
×
" clinical trials "
×
" san francisco blog main "
×
" boston top stories "
×
@xconomy.com
3 years ago
Grail Files to Go Public; 5 More Life Science Firms Join the IPO Queue
@xconomy.com
3 years ago
Bio Roundup: Pharma M&A, AbbVie’s Cancer Bet, Biofourmis Bucks & More
@xconomy.com
3 years ago
Biofourmis Hauls In $100M to Scale Digital Therapeutics Globally
@xconomy.com
4 years ago
Biotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
@xconomy.com
4 years ago
Bio Roundup: MedCo’s Pricing Plan, Vertex’s Gamble, uBiome Undone
@xconomy.com
4 years ago
Bio Roundup: Sarepta’s Stumble, Opioid Suits, Shkreli’s Legacy & More
@xconomy.com
5 years ago
Bio Roundup: Head and Spine Previews, Biogen Moves, IPO Dreams & More
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
ASH 2018: A Guide to the Latest for Blood-Borne Cancers and More
@xconomy.com
6 years ago
Amgen Migraine Drug Gets FDA Nod, First in New Class of Medicines